Total Valuation
Tvardi Therapeutics has a market cap or net worth of CHF15.93M. The enterprise value is CHF4.53M.
Market CapCHF15.93M
Enterprise ValueCHF4.53M
Share Statistics
Tvardi Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders8.15%
Owned by Institutions0.67%
Financial Efficiency
Tvardi Therapeutics’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -126.49%.
Return on Equity (ROE)-0.87
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-126.49%
Return on Capital Employed (ROCE)-1.27
Revenue Per Employee0.00
Profits Per Employee-1.52M
Employee Count12
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tvardi Therapeutics is ―. Tvardi Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio1.52
Price to Fair Value1.52
Price to FCF-1.36
Price to Operating Cash Flow―
PEG Ratio0.02
Income Statement
In the last 12 months, Tvardi Therapeutics had revenue of 0.00 and earned -18.21M in profits. Earnings per share was -2.46.
Revenue0.00
Gross Profit-95.00K
Operating Income-26.75M
Pretax Income-18.21M
Net Income-18.21M
EBITDA-18.12M
Earnings Per Share (EPS)-2.46
Cash Flow
In the last 12 months, operating cash flow was -26.50M and capital expenditures 0.00, giving a free cash flow of -26.50M billion.
Operating Cash Flow-26.50M
Free Cash Flow-26.50M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Tvardi Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Tvardi Therapeutics upcoming earnings date is Aug 13, 2026, TBA (Confirmed).
Last Earnings DateMay 8, 2026
Next Earnings DateAug 13, 2026
Ex-Dividend Date―
Financial Position
Tvardi Therapeutics as a current ratio of 2.86, with Debt / Equity ratio of ―
Current Ratio2.86
Quick Ratio2.86
Debt to Market Cap0.00
Net Debt to EBITDA1.13
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tvardi Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tvardi Therapeutics EV to EBITDA ratio is -0.63, with an EV/FCF ratio of -0.48.
EV to Sales0.00
EV to EBITDA-0.63
EV to Free Cash Flow-0.48
EV to Operating Cash Flow-0.48
Balance Sheet
Tvardi Therapeutics has CHF30.81M in cash and marketable securities with CHF174.00K in debt, giving a net cash position of CHF30.61M billion.
Cash & Marketable SecuritiesCHF30.81M
Total DebtCHF174.00K
Net CashCHF30.61M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF2.78
Margins
Gross margin is ―, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin―
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tvardi Therapeutics is CHF8.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF8.29
Price Target Upside― Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast―